Detection of secondary biomarker of met-eGH as a strategy to screen for somatotropin misuse in horseracing.
Abstract: Since the Australian commercialisation of the recombinant equine growth hormone (reGH) in 1998 (EquiGen-5), Bresagen), this reGH, which differs only from eGH by an additional methionine at the N-terminal end (met-eGH), is worldwide suspected to be administered to racehorses as a doping agent. Indeed, the use of this biological drug is considered as a threat to horseracing since it acts both on growth, development or reproductive functions, and on the improvement of performances. In this work, we describe two reliable techniques based on surface plasmon resonance biosensor immunoassay (SPR-BIA) and solid-phase enzyme-linked immunosorbent assay (ELISA) as new, rapid and efficient long-term screening methods applicable to horseracing antidoping analysis. The ELISA and SPR-BIA tests were applied to octanoic acid purified IgGs from serum/plasma samples collected on two thoroughbreds treated with recombinant equine growth hormone for a period of two weeks. The first kinetic study of serum/plasma antibodies raised as a consequence of recombinant equine growth hormone administrations, which allows the detection from eight days up to 200 days after the beginning of the treatment, was performed. In order to trace the occurrence of anti-reGH antibodies in routine analysis and to monitor the animal level exposure to this forbidden molecule, a random population study was conducted on 233 post-race horses.
Publication Date: 2007-12-21 PubMed ID: 18227952DOI: 10.1039/b713712eGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article covers the development of two new testing techniques for the detection of misuse of equine growth hormone (eGH) in racehorses. Using enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance biosensor immunoassay (SPR-BIA), the study conducts a kinetic examination of serum/plasma antibodies in racehorses, offering a potential long-term screening method for this type of doping in the sport of horseracing.
Introduction
- Equine growth hormone (eGH), specifically a version known as recombinant equine growth hormone (reGH), has been suspected for being administered illicitly to racehorses as a doping agent.
- Administering this biological drug is considered a threat to the integrity of horseracing as it can enhance a horse’s performance by influencing its growth, development, and reproductive functions.
- The need to detect this misuse led to the development of two screening methods; surface plasmon resonance biosensor immunoassay (SPR-BIA) and enzyme-linked immunosorbent assay (ELISA).
Development of the Screening Techniques
- The ELISA and SPR-BIA tests were employed on serum/plasma samples collected from two thoroughbreds treated with reGH over a two-week period.
- The study represents the first kinetic investigation of serum/plasma antibodies raised as a result of reGH administrations in racehorses.
- The treatments were detectable from eight days and persisted upto 200 days after initiation.
Population Study and Application
- In addition to the development of the tests, the research included a random population study of 233 post-race horses to trace the occurrence of anti-reGH antibodies and monitor the level of exposure to this banned substance in routine analysis.
- The findings and methodologies presented in the study could potentially provide a fast, reliable, and long-term antidoping screening method for the horseracing industry.
Cite This Article
APA
Bailly-Chouriberry L, Chu-Van E, Pinel G, Garcia P, Popot MA, André-Fontaine G, Bonnaire Y, Le Bizec B.
(2007).
Detection of secondary biomarker of met-eGH as a strategy to screen for somatotropin misuse in horseracing.
Analyst, 133(2), 270-276.
https://doi.org/10.1039/b713712e Publication
Researcher Affiliations
- LABERCA, Ecole Nationale Vétérinaire de Nantes, Nantes, France. laberca@vet-nantes.fr
MeSH Terms
- Animals
- Antibody Specificity
- Biomarkers / blood
- Biosensing Techniques
- Blotting, Western / methods
- Doping in Sports / prevention & control
- Enzyme-Linked Immunosorbent Assay / methods
- Growth Hormone / immunology
- Horses / immunology
- Immunoglobulin G / blood
- Methionine / immunology
- Recombinant Proteins / immunology
Citations
This article has been cited 3 times.- Raux A, Bichon E, Benedetto A, Pezzolato M, Bozzetta E, Le Bizec B, Dervilly G. The Promise and Challenges of Determining Recombinant Bovine Growth Hormone in Milk. Foods 2022 Jan 20;11(3).
- Narduzzi L, Buisson C, Morvan ML, Marchand A, Audran M, Le Bouc Y, Varlet-Marie E, Ericsson M, Le Bizec B, Dervilly G. Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective. Front Mol Biosci 2021;8:683675.
- Richens JL, Urbanowicz RA, Lunt EA, Metcalf R, Corne J, Fairclough L, O'Shea P. Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. Respir Res 2009 Apr 22;10(1):29.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
